Sundry Photography/iStock Editorial via Getty Images Johnson & Johnson’s ( NYSE: JNJ ) chemotherapy-free drug combination has been cleared in the U.S. for the first-line treatment of patients with EGFR-mutated advanced lung cancer.
The FDA approval is based on positive results from the Phase 3 MARIPOSA study, which showed Rybrevant plus Lazcluze reduced the risk of disease progression or death by 30% compared to osimertini (median progression-free survival [PFS]: 23.7 months versus 16.6 months) in the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer (NSCLC).
The median duration of response was nine months longer with Rybrevant plus Lazcluze versus osimertinib (25.8 months versus 16.7 months), a secondary endpoint of the study.
The drug combo becomes the first and only chemotherapy-free regimen showing superior superiority versus osimertinib approved for the first-line treatment of patients with EGFR-mutated NSCLC. More on Johnson & Johnson 4 Positives For Johnson & Johnson Johnson & Johnson: Seriously Undervalued At Peak Pessimism Johnson & Johnson Q2: Robust New Product Pipeline J&J, Roche come out on top in S&P ratings of strongest pharma companies J&J expected to declare voting support for talc bankruptcy plan as early as Friday.
